Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $1.1 billion.

  • Apellis Pharmaceuticals' Liabilities and Shareholders Equity rose 17.39% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 billion, marking a year-over-year increase of 4.24%. This contributed to the annual value of $885.1 million for FY2024, which is 12.21% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Liabilities and Shareholders Equity stood at $1.1 billion, which was up 28.89% from $821.4 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $1.1 billion in Q1 2022 and a low of $525.7 million during Q3 2021.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $885.1 million (2024), whereas its average is $882.9 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Liabilities and Shareholders Equity tumbled by 31.58% in 2021, and later surged by 66.05% in 2022.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Liabilities and Shareholders Equity stood at $881.8 million in 2021, then fell by 13.78% to $760.2 million in 2022, then climbed by 3.75% to $788.7 million in 2023, then rose by 12.21% to $885.1 million in 2024, then grew by 17.39% to $1.1 billion in 2025.
  • Its Liabilities and Shareholders Equity was $1.1 billion in Q3 2025, compared to $821.4 million in Q2 2025 and $807.3 million in Q1 2025.